Univariate and multivariate survival analyses according to on-treatment factors at 2 weeks after the start of sorafenib therapy.

HR, hazard ratio; CI, confidence interval; CE-CT, contrast-enhanced computed tomography; AFP, alpha-fetoprotein; CP, Child-Pugh.
Univariate and multivariate survival analyses according to on-treatment factors at 2 weeks after the start of sorafenib therapy.

风险比（HR, hazard ratio）、置信区间（CI, confidence interval）、增强计算机断层扫描（CE-CT, contrast-enhanced computed tomography）、甲胎蛋白（AFP, alpha-fetoprotein）以及CP（Child-Pugh）。基于索拉非尼治疗开始后2周的治疗中因素开展的单因素与多因素生存分析。